Knight Therapeutics Inc. has filed a supplemental application with Brazil's health regulatory agency, ANVISA, to expand the approved use of MINJUVI (tafasitamab). The company is seeking to position the drug as a first-line treatment for adults with untreated high-grade B-cell lymphoma (HGBL) or diffuse large B-cell lymphoma (DLBCL).
Project Orbis and the Push for First-Line MINJUVI Approval
The application submitted by Knight Therapeutics Inc. proposes using MINJUVI (tafasitamab) in combination with R-CHOP and lenalidomide. According to the report, this specific supplemental application has been selected for review under Project Orbis, an international framework designed to allow concurrent submission and review of oncology products among global regulators to speed up patient access.
By utilizing Project Orbis, Knight Therapeutics Inc. aims to streamline the regulatory pathway in Brazil... The goal is to transition tafasitamab from a treatment used in later stages of the disease to a primary intervention for patients who have not yet received therapy, potentially altering the standard of care for aggressive B-cell malignancies in the region.
Addressing 39,012 Cases of DLBCL in Brazil
The scale of the medical need in South America is significant. Data from the Brazilian Public Unified Healthcare System's Department of Information Technology (DataSUS) indicates that diffuse large B-cell lymphoma (DLBCL) was the most frequently diagnosed non-Hodgkin lymphoma in Brazil, with 39,012 cases reported between 2008 and 2017. As the most common type of non-Hodgkin lymphoma worldwide, DLBCL often manifests as rapidly growing masss or enlarged lymph nodes.
This high prevalence makes the Brazilian market a critical focal point for Knight Therapeutics Inc.. Because DLBCL accounts for up to a third of all non-Hodgkin lymphoma cases globally, the introduction of a more effective first-line therapy could have a substantial impact on public health outcomes in Brazil, where the disease burden remains high.
The 40% Failure Rate of Initial DLBCL Therapies
A primary driver for this application is the fact that approximately 40% of patients with diffuse large B-cell lymphoma either do not respond to their initial therapy or suffer a relapse. This gap in efficacy creates a critical unmet need, particularly for those with high-grade B-cell lymphoma (HGBL), a rare and aggressive category defined by the World Health Organization (WHO) based on specific genetic rearrangements of MYC and BCL2.
According to the report, Knight Therapeutics Inc. is leveraging "encouraging" clinical data to argue that adding tafasitamab to the initial treatment regimen can improve these outcomes. By targeting the disease more aggressively at the start, the company hopes to reduce the number of patients who fall into that 40% failure bracket.
Existing Approvals in Japan and Europe for Follicular Lymphoma
The push for first-line approval in Brazil follows a pattern of established success for tafasitamab in other markets and indications.. MINJUVI has already been approved in Brazil, Japan, and Europe for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), provided it is used in combination with rituximab and lenalidomide.
This existing regulatory footprint suggests that ANVISA is already familiar with the safety profile of tafasitamab. The current move by Knight Therapeutics Inc. is less about introducing a new molecule to the Brazilian market and more about expanding the clinical utility of a known agent to a more urgent, first-line settiing for more aggressive lymphoma subtypes.
The Incyte Distribution Deal and Unspecified Clinical Timelines
Knight Therapeutics Inc. operates this initiative through an exclusive supply and distribution agreement with Incyte,which holds the rights to tafasitamab. While the company expresses confidence in the clinical data, the specific metrics of the "encouraging" results—such as progression-free survival rates or overall response rates compared to R-CHOP alone—were not detailed in the announcement.
Furthermore, it remains unlear exactly when ANVISA will issue a final decision on the supplemental application. While Project Orbis accelerates the process, the timeline for integration into the Brazilian public health system, beyond the initial regulatory approval, remains an open question.
Comments 0